SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Cannabis >

Nemus Bioscience, Inc. (NMUS)

NMUS RSS Feed
Add NMUS Price Alert      Hide Sticky   Hide Intro
Moderator: Paulieme
Search This Board: 
Last Post: 10/16/2017 12:17:47 PM - Followers: 110 - Board type: Free - Posts Today: 0


 

 NEMUS BIOSCIENCE™ provides pharmaceutical research and development services focused on discovering, developing, and commercializing new chemical entities from a class of chemically diverse compounds. We develop novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

NEMUS Bioscience Inc., a Nevada corporation, is a SEC fully reporting company listed on the  under the symbol NMUS.

Company Website:  http://www.nemusbioscience.com/home.html

Filings and disclosure with Level 2 quotes:  http://www.otcmarkets.com/stock/NMUS/quote

Contact:

(949) 396-0330
E-MAIL: BRIAN@NEMUSBIO.COM
600 ANTON BLVD, SUITE 1100, COSTA MESA, CA 92626


 

Nemus Bioscience (NMUS) Presentation (47 minutes):  
https://www.youtube.com/watch?v=tYV2PEaj6os

Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 12th, 2016: 
http://s2.q4cdn.com/753474459/files/doc_presentations/2016/Rodman-Conf-September-2016_FINAL.pdf



 


Major press releases:

A Sit Down With Nemus Bioscience; Cannabinoids In Focus Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)  
 

Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions -


Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy


Nemus Bioscience Announces Presentation of NB1111 Impact on Intraocular Pressure (IOP) in Normotensive Ocular Model at the National Meeting of the American Association of Pharmaceutical Scientists (AAPS)

 

Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model

 

Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.


NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 


CANNAINVESTOR Magazine Top 20 Cannabis Stocks 

 

NEMUS Bioscience CEO to Present at the 28th Annual ROTH Conference 

 

NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients 

 

NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development 

 

Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN) 

 

NMUS Security Details

Share Structure - as of Feb 1, 2017
Source: otcmarkets.com

Authorized Shares: 236,000,000
Outstanding Shares: 
22,438,163
      - Restricted  13,494,621
    - Unrestricted   8,943,542

           - Float   5,005,713 a/o Mar 23, 2016 
   Par Value 0.001


Transfer Agent: Clear Trust, LLC

SureTrader
Interactive Brokers Advertisement
NMUS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 10/13/2017 04:36:49 PM
NMUS News: Current Report Filing (8-k) 10/13/2017 04:35:04 PM
NMUS News: MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing 08/30/2017 10:29:33 PM
NMUS News: PotNetwork Holdings, Inc Confirmed for MJAC 2017 08/28/2017 10:43:55 AM
NMUS News: MJAC 2017 International Cannabis Conference - Discount Code 08/25/2017 06:50:56 PM
PostSubject
#2747   just to be clear AntonChigurh 09/10/17 11:16:37 PM
#2746   I took a quick look and didn't see cjarmstrong 09/09/17 01:53:36 AM
#2745   No advisors have equity AFAIK Never announced in PR AntonChigurh 09/08/17 09:57:06 PM
#2744   What costs? Advisers usually are paid in equity cjarmstrong 09/08/17 09:06:40 PM
#2743   Maybe they couldn't afford the costs involved on AntonChigurh 09/08/17 02:13:25 PM
#2742   Robert Weinreb was removed from Nemus' site sometime cjarmstrong 09/08/17 01:20:38 PM
#2741   They don't do fake news Or news for the AntonChigurh 09/08/17 11:11:06 AM
#2739   Those are questions only Nemus could answer. cjarmstrong 09/07/17 06:46:23 PM
#2738   Why did Dr. Weinreb leave Nemus? He appears in AntonChigurh 09/07/17 01:48:27 PM
#2737   With this low pps and share count, in retired early 09/05/17 02:56:57 PM
#2736   It is new. AntonChigurh 09/05/17 02:19:16 PM
#2735   NEW ARTICLE: Closewatcher 09/05/17 12:02:12 PM
#2734   Nemus Bioscience CEO Talks 'Waves Of Dominance' In AntonChigurh 09/05/17 12:01:45 PM
#2733   Can always count it on the crooks to Closewatcher 09/05/17 10:44:26 AM
#2732   You too. Thank you. Vinpat 09/01/17 03:56:48 PM
#2731   Thank you! Have a good weekend, I guess TURCH 09/01/17 03:51:24 PM
#2730   I have no clue why unless there's some Vinpat 09/01/17 03:50:23 PM
#2729   I came to say the same thing. The Jdanger 2 09/01/17 03:35:10 PM
#2728   Some serious interest today??? Regards TURCH 09/01/17 03:17:25 PM
#2727   My understanding is the agreements were similar to Vinpat 08/31/17 02:26:36 AM
#2726   Vinpat, while your here The licensing agreements. The 60/40 AntonChigurh 08/31/17 02:11:40 AM
#2725   Man you're good. Skibinski is brilliant and has Vinpat 08/31/17 02:02:56 AM
#2724   I finnaly found some info about one of AntonChigurh 08/31/17 01:44:02 AM
#2723   From-DollarsOnPennies - 08/29/17 01:39:39 AM Paulieme 08/30/17 06:58:11 PM
#2722   The financing was set to close July 10th. Schneider AntonChigurh 08/30/17 03:39:55 PM
#2721   Thanks. Any guesses to when that will be? 1990 08/30/17 03:34:09 PM
#2720   The series e financing delay Is what has caused AntonChigurh 08/30/17 03:24:33 PM
#2719   Been holding for a year. This is my 1990 08/30/17 02:52:27 PM
#2718   Well the good thing about August ending is Closewatcher 08/29/17 10:27:46 AM
#2717   $5 is unrealistic, but I would love to cjarmstrong 08/26/17 03:56:06 PM
#2716   Anybody going to the iHub ICC? miracleshappen 08/23/17 05:38:42 PM
#2715   I dont think anybody expects the $20 mill Closewatcher 08/23/17 01:15:51 PM
#2714   Trial of Cannabidiol for Drug-Resistant Seizures in the AntonChigurh 08/23/17 12:49:30 AM
#2713   $20mm isn't that much. G&A costs are $2mm cjarmstrong 08/23/17 12:26:31 AM
#2712   Aug. 18 issue of BioWorld.--- Can Paulieme 08/21/17 05:28:18 PM
#2711   Is Marijuana’s “Entourage Effect” Scientifically Valid? AntonChigurh 08/21/17 02:47:21 AM
#2710   Are you one of those Ban the Fed guys? AntonChigurh 08/21/17 01:24:17 AM
#2709   Generally true, though NB1222 will still be expensive cjarmstrong 08/20/17 04:17:35 PM
#2708   Thanks, Anton. cjarmstrong 08/20/17 02:39:50 PM
#2707   Closewatcher Thank you for that Name AntonChigurh 08/18/17 12:46:40 AM
#2706   Wouldn't get beat up about it. Partnerships for Closewatcher 08/17/17 04:12:17 PM
#2705   You ask tough questions CJ AntonChigurh 08/17/17 02:59:04 PM
#2704   You're right, biotech is a capital intensive industry cjarmstrong 08/17/17 02:30:53 PM
#2703   the 'downtrend' AntonChigurh 08/17/17 01:07:33 PM
#2702   Its par for the course in biotech. This Closewatcher 08/17/17 10:24:24 AM
#2701   I said basic shares, which right now is cjarmstrong 08/17/17 02:28:46 AM
#2700   the Series C guys AntonChigurh 08/17/17 02:26:14 AM
#2699   Were at 40M fully diluted AntonChigurh 08/16/17 03:17:35 PM
#2698   Unfortunately the stock has basically been bearish since cjarmstrong 08/16/17 02:57:51 PM
#2697   There's no volume because there are only about Vinpat 08/16/17 02:56:03 PM
PostSubject